HRP20000494B1 - Pharmaceutically active morpholinol - Google Patents

Pharmaceutically active morpholinol

Info

Publication number: HRP20000494B1
Authority: HR; Croatia
Prior art keywords: pharmaceutically active; morpholinol; pharmaceutically acceptable; active morpholinol; solvates
Prior art date: 1998-01-21

Application number

HR20000494A

Other languages

English (en)

Croatian (hr)

Inventor

Frederick Morgan Phillip

Lee Musso David

Joseph Partridge John

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

2000-07-21

Publication date

2009-02-28

1998-01-21 Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en

2000-07-21 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2000-12-31 Publication of HRP20000494A2 publication Critical patent/HRP20000494A2/hr

2009-02-28 Publication of HRP20000494B1 publication Critical patent/HRP20000494B1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HR20000494A 1998-01-21 2000-07-21 Pharmaceutically active morpholinol HRP20000494B1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9801230.5A GB9801230D0 (en)	1998-01-21	1998-01-21	Pharmaceutically active morpholinol
US7218098P	1998-01-22	1998-01-22
PCT/US1999/001134 WO1999037305A1 (en)	1998-01-21	1999-01-20	Pharmaceutically active morpholinol

Publications (2)

Publication Number	Publication Date
HRP20000494A2 HRP20000494A2 (en)	2000-12-31
HRP20000494B1 true HRP20000494B1 (en)	2009-02-28

Family

ID=26312986

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HR20000494A HRP20000494B1 (en)	1998-01-21	2000-07-21	Pharmaceutically active morpholinol
HR20051024A HRP20051024A2 (hr)	1998-01-21	2005-12-29	Farmaceutski aktivni morfolinol

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HR20051024A HRP20051024A2 (hr)	1998-01-21	2005-12-29	Farmaceutski aktivni morfolinol

Country Status (30)

Country	Link
US (2)	US6274579B1 (no)
EP (2)	EP1047428B1 (no)
JP (1)	JP2002501025A (no)
KR (1)	KR100568063B1 (no)
CN (2)	CN1203858C (no)
AP (1)	AP1229A (no)
AT (1)	ATE365042T1 (no)
AU (1)	AU755536B2 (no)
BR (1)	BR9907203A (no)
CA (1)	CA2318268A1 (no)
CY (1)	CY1106828T1 (no)
DE (1)	DE69936335T2 (no)
DK (1)	DK1047428T3 (no)
EA (1)	EA002410B1 (no)
EE (1)	EE04452B1 (no)
ES (1)	ES2288012T3 (no)
HR (2)	HRP20000494B1 (no)
HU (1)	HUP0100900A3 (no)
ID (1)	ID26334A (no)
IL (2)	IL137346A0 (no)
IS (1)	IS2494B (no)
NO (2)	NO326878B1 (no)
NZ (3)	NZ505809A (no)
PL (1)	PL193622B1 (no)
PT (1)	PT1047428E (no)
SG (1)	SG115489A1 (no)
SK (1)	SK10912000A3 (no)
TR (1)	TR200002126T2 (no)
WO (1)	WO1999037305A1 (no)
YU (1)	YU67102A (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7098206B2 (en) *	1998-01-21	2006-08-29	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6998400B2 (en) *	1998-01-22	2006-02-14	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
JP2002501891A (ja) *	1998-01-29	2002-01-22	セプラコアインコーポレーテッド	光学的に純粋な（＋）−ビュープロピオンの医薬用途
CA2318920A1 (en)	1998-01-29	1999-08-05	James W. Young	Pharmaceutical uses of optically pure (-)-bupropion
US6734213B2 (en)	1999-01-20	2004-05-11	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6855820B2 (en)	1999-01-20	2005-02-15	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6342496B1 (en) *	1999-03-01	2002-01-29	Sepracor Inc.	Bupropion metabolites and methods of use
US6337328B1 (en) *	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
AU7750100A (en) *	1999-10-13	2001-04-23	Glaxo Group Limited	Method for the treatment of obesity
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
US7145649B2 (en) *	2000-12-21	2006-12-05	Brasscorp Limited	Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en)	2001-12-31	2005-12-27	R.J. Doran & Co. LTD	LED inspection lamp
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
KR20110043664A (ko) *	2002-05-17	2011-04-27	듀크 유니버시티	비만치료방법
AU2003269923A1 (en) *	2002-08-23	2004-03-11	Eli Lilly And Company	2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) *	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
EP2316456B1 (en)	2003-04-29	2017-06-14	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss comprising an opioid antagonist and bupropion
GB0325055D0 (en) *	2003-10-27	2003-12-03	Smithkline Beecham Corp	New process
WO2005042503A1 (en) *	2003-10-27	2005-05-12	Smithkline Beecham Corporation	Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
GB0326148D0 (en) *	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
GB0327195D0 (en) *	2003-11-21	2003-12-24	Smithkline Beecham Corp	Novel use
GB0327619D0 (en) *	2003-11-27	2003-12-31	Smithkline Beecham Corp	New use
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
JP2007517901A (ja)	2004-01-13	2007-07-05	デューク・ユニバーシティー	体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US20050277579A1 (en) *	2004-05-03	2005-12-15	Ranga Krishnan	Compositions for affecting weight loss
FI117283B (fi)	2005-02-04	2006-08-31	Kone Corp	Hissijärjestelmä
PT2135603E (pt)	2005-11-22	2013-04-03	Orexigen Therapeutics Inc	Composições e métodos para aumentar a sensibilidade à insulina
CA2635261A1 (en) *	2006-01-03	2007-07-12	Algebra, Inc.	Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
KR101479324B1 (ko)	2006-11-09	2015-01-05	오렉시젠 세러퓨틱스 인크.	신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en)	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
US20090075994A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched radafaxine
EP2303025A4 (en)	2008-05-30	2012-07-04	Orexigen Therapeutics Inc	METHOD FOR TREATING DIGITAL FAT SWITCHES
AU2010236404B2 (en)	2009-04-15	2016-11-03	Research Triangle Institute	Monoamine reuptake inhibitors
US9248123B2 (en)	2010-01-11	2016-02-02	Orexigen Therapeutics, Inc.	Methods of providing weight loss therapy in patients with major depression
ES2687095T3 (es)	2010-05-21	2018-10-23	Research Triangle Institute	Fenilimorfolinas y análogos de las mismas
ES2546492T3 (es)	2010-05-21	2015-09-24	Research Triangle Institute	Derivados de 1-fenilmorfolina como análogos de hidroxibupropion para tratar drogodependencia
US9510405B2 (en)	2011-06-30	2016-11-29	Schneider Electric Industries Sas	Dual power SMPS for a modular lighting system
CN102670617B (zh) *	2012-04-13	2013-03-20	湖南大学	布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
KR20200035501A (ko)	2012-06-06	2020-04-03	오렉시젠 세러퓨틱스 인크.	과체중 및 비만의 치료 방법
CN105949142B (zh) *	2016-05-21	2018-03-27	南华大学	具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) *	2021-06-17	2021-12-30	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US170430A (en) *		1875-11-30		Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) *	1984-07-05	1984-08-08	Wellcome Found	Heterocyclic pharmaceutical compounds
GB9108629D0 (en)	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use

1999
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active IP Right Cessation
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en active IP Right Grant
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
- 2000-07-21 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
2005
- 2005-12-29 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR100568063B1 (ko)	2006-04-07
CN1203858C (zh)	2005-06-01
AU2328099A (en)	1999-08-09
KR20010034285A (ko)	2001-04-25
PL342012A1 (en)	2001-05-07
NO20083529L (no)	2000-09-19
ES2288012T3 (es)	2007-12-16
CA2318268A1 (en)	1999-07-29
IS2494B (is)	2009-02-15
AU755536B2 (en)	2002-12-12
IS5568A (is)	2000-07-20
CN1528753A (zh)	2004-09-15
EA200000691A1 (ru)	2001-04-23
CY1106828T1 (el)	2012-05-23
WO1999037305A1 (en)	1999-07-29
NO20003721D0 (no)	2000-07-20
DE69936335T2 (de)	2008-02-28
EP1047428B1 (en)	2007-06-20
PL193622B1 (pl)	2007-02-28
DE69936335D1 (de)	2007-08-02
YU67102A (sh)	2004-12-31
HUP0100900A2 (hu)	2002-05-29
BR9907203A (pt)	2000-10-17
EP1047428A4 (en)	2001-12-19
US6274579B1 (en)	2001-08-14
HRP20000494A2 (en)	2000-12-31
IL161942A0 (en)	2005-11-20
JP2002501025A (ja)	2002-01-15
IL137346A0 (en)	2001-07-24
NZ520349A (en)	2004-02-27
DK1047428T3 (da)	2007-10-08
NZ529316A (en)	2004-05-28
SG115489A1 (en)	2005-10-28
AP1229A (en)	2003-12-04
ID26334A (id)	2000-12-14
EP1829544A1 (en)	2007-09-05
NO326878B1 (no)	2009-03-09
TR200002126T2 (tr)	2000-12-21
ATE365042T1 (de)	2007-07-15
HRP20051024A2 (hr)	2006-04-30
EP1047428A1 (en)	2000-11-02
EA002410B1 (ru)	2002-04-25
CN1255389C (zh)	2006-05-10
US6391875B2 (en)	2002-05-21
PT1047428E (pt)	2007-09-07
AP2000001869A0 (en)	2000-09-30
EE200000438A (et)	2001-12-17
EE04452B1 (et)	2005-04-15
NO20003721L (no)	2000-09-19
SK10912000A3 (sk)	2001-04-09
HUP0100900A3 (en)	2002-08-28
NZ505809A (en)	2002-09-27
CN1294513A (zh)	2001-05-09
US20020019396A1 (en)	2002-02-14

Publication	Publication Date	Title
HRP20000494B1 (en)	2009-02-28	Pharmaceutically active morpholinol
RS50485B (sr)	2010-03-02	Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
NZ507221A (en)	2003-04-29	Antitumor agent
FI950947A0 (fi)	1995-03-01	Oraalisesti annettavat farmaseuttiset formulaatiot
DE60039291D1 (de)	2008-08-07	Camptothecinanaloge und deren zubereitungsmethoden
BR9710372B1 (pt)	2013-02-05	composto, e, composiÇço farmacÊutica.
NO20015477D0 (no)	2001-11-08	4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler
TR200200579T2 (tr)	2002-12-23	Amino-tirazolpiridin türevleri.
CA2326222A1 (en)	1999-11-04	Medicinal compositions
TR199901077A3 (tr)	1999-12-21	Ispençiyari formülasyonlar.
PT960107E (pt)	2003-02-28	Compostos de paclitaxel 6-tio-substituidos
RS50352B (sr)	2009-11-10	Monosupstituisane 3-propil gama-aminobuterne kiseline
ZA200201509B (en)	2003-04-30	Pharmaceutically active sulfonamide derivatives.
NO976074L (no)	1998-03-02	To- og treverdige småmolekylinhibitorer for selektin
IT1302682B1 (it)	2000-09-29	Composizioni farmaceutiche orali contenenti buprenorfina
DE69915487D1 (de)	2004-04-15	Erythromycin-derivate mit antibiotischer wirkung
DZ1576A1 (fr)	2002-02-17	Compostions therapeutiques à base de dérives de 1,2-dithiole-3-thione.
HRP20000400B1 (en)	2009-06-30	Transmucosal formulations of levosimendal
EP1073447A4 (en)	2001-10-04	N1-MODIFIED GLYCOPEPTIDES
EA200101150A1 (ru)	2002-04-25	Раствор прукалоприда для перорального применения
ES2192789T3 (es)	2003-10-16	Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
EP0816366A4 (en)	1998-07-08	IMIDAZOTHIAZOL COMPOUNDS
FR2668697B1 (fr)	1997-06-06	Dissecteur, notamment pour chirurgie endoscopique.
SE9701438D0 (sv)	1997-04-17	A new process
ATE491709T1 (de)	2011-01-15	Pyrrolidinohydrochinazoline

Legal Events

Date	Code	Title	Description
2000-12-31	A1OB	Publication of a patent application
2001-06-21	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2009-02-28	B1PR	Patent granted
2012-01-18	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20120118 Year of fee payment: 14
2013-07-21	PBON	Lapse due to non-payment of renewal fee	Effective date: 20130121